Spyre Therapeutics, Inc. (SYRE) stock
SYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/30
$101.46+7.65 (+8.15%)
Close on Nov 18, 2026Market cap $8.95BP/E –Yield –
Spyre Therapeutics EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
No ev/ebitda figures for Spyre Therapeutics
Spyre Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?